References
- Li J, Liu W. Puzzle of highly pathogenic human coronaviruses (2019-nCoV). Protein Cell. 2020;11(4):235–238. Available from: http://link.springer.com/10.1007/s13238-020-00693-y
- Chen J. Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses. Microbes Infect. 2020;22(2):69–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32032682
- Liu C, Zhou Q, Li Y, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci. 2020;6(3):315–331. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32226821
- Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181–192. Available from: http://www.nature.com/articles/s41579-018-0118-9
- Woo PCY, Lau SKP, Lam CSF, et al. Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavi. J Virol. 2012;86(7):3995–4008. Available from: https://jvi.asm.org/content/86/7/3995
- Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418–423. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25681
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673620301835
- Mahase E. Coronavirus: COVID-19 has killed more people than SARS and MERS combined, despite lower case fatality rate. BMJ. 2020;m641. Available from https://www.bmj.com/lookup/doi/10.1136/bmj.m641
- WHO. WHO Coronavirus Disease (COVID-19) dashboard. data last updat. 2021 January 10. 2021. Available from: https://COVID19.who.int/.
- Tang B, Bragazzi NL, Li Q, et al. An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov). Infect Dis Model. 2020;5(5):248–255. Available from: https://linkinghub.elsevier.com/retrieve/pii/S246804272030004X
- Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. 2015. p. 1–23. [cited 2015 Feb 12]. Available from: http://link.springer.com/10.1007/978-1-4939-2438-7_1.
- Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490–502. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0966842X16000718
- Lai -C-C, Shih T-P, Ko W-C, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0924857920300674
- Morse JS, Lalonde T, Xu S, et al. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem. 2020;21(5):730–738. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32022370
- Li X, Geng M, Peng Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102–108. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2095177920302045
- Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0092867420302294
- Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. (80-). 2020;367(6483):1260–1263. Available from https://www.sciencemag.org/lookup/doi/10.1126/science.abb2507
- Macchiagodena M, Pagliai M, Procacci P. Inhibition of the main protease 3CL-pro of the coronavirus disease 19 via structure-based ligand design and molecular modeling. 2020. [cited 2020 Feb 23]. Available from: http://arxiv.org/abs/2002.09937.
- De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Anti Infect Ther. 2006;4(2):291–302. Available from: http://www.tandfonline.com/doi/full/10.1586/14787210.4.2.291
- Wang Y, Sun Y, Wu A, et al. Coronavirus nsp10/nsp16 methyltransferase can be targeted by nsp10-derived peptide in vitro and in vivo to reduce replication and pathogenesis. J Virol. 2015;89(16):8416–8427. Available from: https://jvi.asm.org/content/89/16/8416
- Thakur N, Qureshi A, Kumar M. AVPpred: collection and prediction of highly effective antiviral peptides. Nucleic Acids Res. 2012;40:W199–W204. Available from https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gks450
- Lcp VB, Campos ML, Berlanda RLA, et al. Antiviral peptides as promising therapeutic drugs. Cell Mol Life Sci. 2019;76(18):3525–3542. Available from: http://link.springer.com/10.1007/s00018-019-03138-w
- Da Mata ÉCG, Cbf M, Rangel M, et al. Antiviral activity of animal venom peptides and related compounds. J Venom Anim Toxins Incl Trop Dis. 2017;23(1):3. Available from: http://jvat.biomedcentral.com/articles/10.1186/s40409-016-0089-0
- Huan Y, Kong Q, Mou H, et al. Antimicrobial Peptides: classification, design, application and research progress in multiple fields. Front Microbiol. 2020;11:11. Available from https://www.frontiersin.org/article/10.3389/fmicb.2020.582779/full
- Chen CH, Lu TK. Development and challenges of antimicrobial peptides for therapeutic applications. Antibiotics. 2020;9(1):24. Available from: https://www.mdpi.com/2079-6382/9/1/24
- Sala A, Ardizzoni A, Ciociola T, et al. Antiviral activity of synthetic peptides derived from physiological proteins. Intervirology. 2018;61(4):166–173. Available from: https://www.karger.com/Article/FullText/494354
- Mahlapuu M, Håkansson J, Ringstad L, et al. Antimicrobial peptides: an emerging category of therapeutic agents. Front Cell Infect Microbiol. 2016; 6 Available from: http://journal.frontiersin.org/article/10.3389/fcimb.2016.00194/full
- Falco A, Ortega-Villaizan M, Chico V, et al. Antimicrobial peptides as model molecules for the development of novel antiviral agents in aquaculture. Mini-Rev Med Chem. 2009;9(10):1159–1164. Available from: http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1389-5575&volume=9&issue=10&spage=1159
- Chang KY, Yang J-R, Isalan M, Analysis and prediction of highly effective antiviral peptides based on random forests. PLoS One. Isalan M, editor . 2013;8:e70166. Available from. ;(8):. https://dx.plos.org/10.1371/journal.pone.0070166
- Mulder KCL, Lima LA, Miranda VJ, et al. Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides. Front Microbiol. 2013;44. Available from: http://journal.frontiersin.org/article/10.3389/fmicb.2013.00321/abstract
- Jung Y, Kong B, Moon S, et al. Envelope-deforming antiviral peptide derived from influenza virus M2 protein. Biochem Biophys Res Commun. 2019;517(3):507–512. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0006291X19314421
- Matsubara T, Onishi A, Saito T, et al. Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy. J Med Chem. 2010;53(11):4441–4449. Available from.
- Jenssen H, Hamill P, Hancock REW. Peptide antimicrobial agents. Clin Microbiol Rev. 2006;19(3):491–511. Available from: https://cmr.asm.org/content/19/3/491
- Skalickova S, Heger Z, Krejcova L, et al. Perspective of use of antiviral peptides against influenza virus. Viruses. 2015;7(10):5428–5442. Available from.
- Gwyer Findlay E, Currie SM, Davidson DJ. Cationic host defence peptides: potential as antiviral therapeutics. BioDrugs. 2013;27(5):479–493. Available from: http://link.springer.com/10.1007/s40259-013-0039-0
- Findlay F, Proudfoot L, Stevens C, et al. Cationic host defense peptides; novel antimicrobial therapeutics against category A pathogens and emerging infections. Pathog Glob Health. 2016;110(4–5):137–147. Available from. https://www.tandfonline.com/doi/full/10.1080/20477724.2016.1195036.
- Holly MK, Diaz K, Smith JG. Defensins in viral infection and pathogenesis. Annu Rev Virol. 2017;4(1):369–391. Available from: http://www.annualreviews.org/doi/10.1146/annurev-virology-101416-041734
- Salvatore M, García‐Sastre A, Ruchala P, et al. α‐defensin inhibits influenza virus replication by cell‐mediated mechanism(s). J Infect Dis. 2007;196(6):835–843.
- Ding J, Chou -Y-Y, Chang TL. Defensins in viral infections. J Innate Immun. 2009;1(5):413–420. Available from: https://www.karger.com/Article/FullText/226256
- Ahmed A, Siman-Tov G, Hall G, et al. Human antimicrobial peptides as therapeutics for viral infections. Viruses. 2019;11(8):704. Available from:https://www.mdpi.com/1999-4915/11/8/704
- Wu Z, Cocchi F, Gentles D, et al. Human neutrophil α-defensin 4 inhibits HIV-1 infection in vitro. FEBS Lett. 2005;579(1):162–166.
- Wang A, Chen F, Wang Y, et al. Enhancement of antiviral activity of human alpha-defensin 5 against herpes simplex virus 2 by arginine mutagenesis at adaptive evolution sites. J Virol. 2013;87(5):2835–2845. Available from: https://jvi.asm.org/content/87/5/2835
- Wiens ME, Smith JG, Imperiale MJ, Alpha-defensin HD5 inhibits furin cleavage of human papillomavirus 16 l2 to block infection. J Virol. Imperiale MJ, editor. 2015;89(5): 2866–2874. Available from: https://jvi.asm.org/content/89/5/2866
- Tenge VR, Gounder AP, Wiens ME, et al. Delineation of interfaces on human alpha-defensins critical for human adenovirus and human papillomavirus inhibition. PLoS Pathog. Robertson ES, editor. 2014;10(9):e1004360. Available from: https://dx.plos.org/10.1371/journal.ppat.1004360
- Kota S, Sabbah A, Chang TH, et al. Role of human β-defensin-2 during tumor necrosis factor-α/NF-κB-mediated innate antiviral response against human respiratory syncytial virus. J Biol Chem. 2008;283(33):22417–22429. Available from: http://www.jbc.org/lookup/doi/10.1074/jbc.M710415200
- Yongjie W, Xiaoyu L, Ming Q, et al. A study on antiviral activity of defensins from neutrophil of human and rabbit against SARS coronavirus in vitro. Jie Fang Jun Yi Xue Za Zhi. 2004;29:1079–1081.
- Wohlford-Lenane CL, Meyerholz DK, Perlman S, et al. Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease. J Virol. 2009;83(21):11385–11390. Available from: https://jvi.asm.org/content/83/21/11385
- Tecle T, Tripathi S, Hartshorn KL. Review: defensins and cathelicidins in lung immunity. Innate Immun. 2010;16(3):151–159. Available from: http://journals.sagepub.com/doi/10.1177/1753425910365734
- Zhang H, Porro G, Orzech N, et al. Neutrophil defensins mediate acute inflammatory response and lung dysfunction in dose-related fashion. Am J Physiol Cell Mol Physiol. 2001;280(5):L947–L954. Available from: https://www.physiology.org/doi/10.1152/ajplung.2001.280.5.L947
- White MR, Doss M, Boland P, et al. Innate immunity to influenza virus: implications for future therapy. Expert Rev Clin Immunol. 2008;4(4):497–514.
- Hartshorn KL, White MR, Tecle T, et al. Innate defense against influenza A virus: activity of human neutrophil defensins and interactions of defensins with surfactant protein D. J Immunol. 2006;176(11):6962–6972. Available from: http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.176.11.6962
- Barlow PG, Findlay EG, Currie SM, et al. Antiviral potential of cathelicidins. Future Microbiol. 2014;9(1):55–73. Available from: https://www.futuremedicine.com/doi/10.2217/fmb.13.135
- Choi K-Y Grace, Mookherjee N. Multiple immune-modulatory functions of cathelicidin host defense peptides. Front Immunol. 2012;3. Available from http://journal.frontiersin.org/article/10.3389/fimmu.2012.00149/abstract
- Barlow PG, Svoboda P, Mackellar A, et al. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One. Kovats S, editor. . 2011;6:10. e25333. Available from. https://dx.plos.org/10.1371/journal.pone.0025333
- Zeth K, Sancho-Vaello E. The human antimicrobial peptides dermcidin and LL-37 show novel distinct pathways in membrane interactions. Front Chem. 2017;5:86.
- Tripathi S, Wang G, White M, et al. Antiviral activity of the human cathelicidin, LL-37, and derived peptides on seasonal and pandemic influenza A viruses. PLoS One. Palaniyar N, editor. . 2015;10(4):e0124706. Available from https://dx.plos.org/10.1371/journal.pone.0124706
- Harcourt JL, McDonald M, Svoboda P, et al. Human cathelicidin, LL-37, inhibits respiratory syncytial virus infection in polarized airway epithelial cells. BMC Res Notes. 2016;9(1):11. Available from: http://www.biomedcentral.com/1756-0500/9/11
- Matsumura T, Sugiyama N, Murayama A, et al. Antimicrobial peptide LL-37 attenuates infection of hepatitis C virus. Hepatol Res. 2016;46(9):924–932. Available from: http://doi.wiley.com/10.1111/hepr.12627
- Alagarasu K, Patil PS, Shil P, et al. In-vitro effect of human cathelicidin antimicrobial peptide LL-37 on dengue virus type 2. Peptides. 2017;92:23–30. Available from https://linkinghub.elsevier.com/retrieve/pii/S0196978117301602
- Crane-Godreau MA, Clem KJ, Payne P, et al. Vitamin D deficiency and air pollution exacerbate COVID-19 suppression of antiviral peptide LL37. Front Public Health. 2020;8. Available from https://www.frontiersin.org/article/10.3389/fpubh.2020.00232/full
- Pahar B, Madonna S, Das A, et al. Immunomodulatory role of the antimicrobial LL-37 peptide in autoimmune diseases and viral infections. Vaccines (Basel). 2020;8(3):517. Available from: https://www.mdpi.com/2076-393X/8/3/517
- Currie SM, Gwyer Findlay E, McFarlane AJ, et al. Cathelicidins have direct antiviral activity against respiratory syncytial virus in vitro and protective function in vivo in mice and humans. J Immunol. 2016;196(6):2699–2710. Available from: http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1502478
- Superti F, Agamennone M, Pietrantoni A, et al. Bovine lactoferrin prevents influenza a virus infection by interfering with the fusogenic function of viral hemagglutinin. Viruses. 2019;11(1):51. Available from: http://www.mdpi.com/1999-4915/11/1/51
- Pietrantoni A, Di Biase AM, Tinari A, et al. Bovine lactoferrin inhibits adenovirus infection by interacting with viral structural polypeptides. Antimicrob Agents Chemother. 2003;47(8):2688–2691. Available from: https://aac.asm.org/content/47/8/2688
- Chen J, Fan Y, Lin J, et al. Bovine lactoferrin inhibits dengue virus infectivity by interacting with heparan sulfate, low-density lipoprotein receptor, and DC-SIGN. Int J Mol Sci 1957. Available from. 2017;(18). : http://www.mdpi.com/1422-0067/18/9/1957
- Giansanti F, Massucci MT, Giardi MF, et al. Antiviral activity of ovotransferrin derived peptides. Biochem Biophys Res Commun. 2005;331(1):69–73. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0006291X05006327
- Tahmoorespur M, Azghandi M, Javadmanesh A, et al. A novel chimeric anti-HCV peptide derived from camel lactoferrin and molecular level insight on its interaction with E2. Int J Pept Res Ther. 2020;26(3):1593–1605. Available from: http://link.springer.com/10.1007/s10989-019-09972-7
- Kell DB, Heyden EL, Pretorius E. The biology of lactoferrin, an iron-binding protein that can help defend against viruses and bacteria. Front Immunol. 2020;11. Available from: https://www.frontiersin.org/article/10.3389/fimmu.2020.01221/full
- Liu H, Le TT, Dong H, et al. Iron regulator hepcidin exhibits antiviral activity against hepatitis C virus. PLoS One. Li K, editor. 2012;7(10): e46631. Available from. https://dx.plos.org/10.1371/journal.pone.0046631
- Ehsani S. COVID-19 and iron dysregulation: distant sequence similarity between hepcidin and the novel coronavirus spike glycoprotein. Biol Direct. 2020;15(1):19. Available from: https://biologydirect.biomedcentral.com/articles/10.1186/s13062-020-00275-2
- Cavezzi A, Troiani E. Corrao S. COVID-19 hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clin Pract. 2020; 10: 24–30. Available from https://www.clinicsandpractice.org/index.php/cp/article/view/1271
- Takahashi T, Nomura F, Yokoyama Y, et al. Multiple membrane interactions and versatile vesicle deformations elicited by melittin. Toxins (Basel). 2013;5(4):637–664. Available from. .
- Wachinger M, Saermark T, Erfle V. Influence of amphipathic peptides on the HIV-1 production in persistently infected T lymphoma cells. FEBS Lett. 1992;309(3):235–241. Available from: http://doi.wiley.com/10.1016/0014-5793%2892%2980780-K.
- Yang W, Hu F, Xu X. Bee venom and SARS-CoV-2. Toxicon. 2020;181:69–70.
- Fratellone PM, Tsimis F, Fratellone G. Apitherapy products for medicinal use. J Altern Complement Med. 2016;22(12):1020–1022. Available from: http://www.liebertpub.com/doi/10.1089/acm.2015.0346
- Liscano Y, Oñate-Garzón J, Ocampo-Ibáñez ID. In silico discovery of antimicrobial peptides as an alternative to control SARS-CoV-2. Molecules. 2020;25(23):5535. Available from: https://www.mdpi.com/1420-3049/25/23/5535
- Marcocci ME, Amatore D, Villa S, et al. The amphibian antimicrobial peptide temporin b inhibits in vitro herpes simplex virus 1 infection. antimicrob agents chemother. 2018;62. [cited 2018 Apr 26]. Available from: https://aac.asm.org/content/62/5/e02367-17.
- De Angelis M, Casciaro B, Genovese A, et al. Temporin G, an amphibian antimicrobial peptide against influenza and parainfluenza respiratory viruses: insights into biological activity and mechanism of action. Faseb J. 2021; 352: Available from https://onlinelibrary.wiley.com/doi/10.1096/fj.202001885RR
- Marimuthu SK, Nagarajan K, Perumal SK, et al. Insilico alpha-helical structural recognition of temporin antimicrobial peptides and its interactions with middle east respiratory syndrome-coronavirus. Int J Pept Res Ther. 2020;26(3):1473–1483. Available from: http://link.springer.com/10.1007/s10989-019-09951-y
- Ucar B, Acar T, Pelit Arayici P, et al. Synthesis and applications of synthetic peptides. pept synth. IntechOpen. 2019. Available from https://www.intechopen.com/books/peptide-synthesis/synthesis-and-applications-of-synthetic-peptides
- Zhao H, Zhou J, Zhang K, et al. A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci Rep. 2016;6(1):22008.
- Kim J, Yang YL, Jang S-H, et al. Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity. Virol J. 2018;15(1):124.
- Dai C, Ma Y, Zhao Z, et al. Mucroporin, the first cationic host defense peptide from the venom of lychas mucronatus. Antimicrob Agents Chemother. 2008;52(11):3967–3972. Available from: https://aac.asm.org/content/52/11/3967
- Li Q, Zhao Z, Zhou D, et al. Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. Peptides. 2011;32(7):1518–1525. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0196978111002075
- Spiegel M, Pichlmair A, Mühlberger E, et al. The antiviral effect of interferon-beta against SARS-Coronavirus is not mediated by MxA protein. J Clin Virol. 2004;30(3):211–213. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1386653203003251
- Nile SH, Nile A, Qiu J, et al. COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020;53:66–70. Available from https://linkinghub.elsevier.com/retrieve/pii/S1359610120300708
- Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149–150. Available from: http://www.nature.com/articles/d41573-020-00016-0
- Ahmed CM, Johnson HM. Short peptide type i interferon mimetics: therapeutics for experimental allergic encephalomyelitis, melanoma, and viral infections. J Interf Cytokine Res. 2014;34(10):802–809. Available from: http://www.liebertpub.com/doi/10.1089/jir.2014.0041
- Belouzard S, Millet JK, Licitra BN, et al. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012;4(6):1011–1033. Available from: http://www.mdpi.com/1999-4915/4/6/1011
- Pan C, Liu S, Jiang S. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics. J Formos Med Assoc. 2010;109(2):94–105. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0929664610600290
- Tang X, Jin H, Chen Y, et al. A membrane-anchored short-peptide fusion inhibitor fully protects target cells from infections of human immunodeficiency virus Type 1 (HIV-1), HIV-2, and simian immunodeficiency virus. J Virol. [ Kirchhoff F, editor. . 2019;93. Available from]. ;(22): https://jvi.asm.org/content/93/22/e01177-19
- Calligari P, Bobone S, Ricci G, et al. Molecular Investigation of SARS–CoV-2 proteins and their interactions with antiviral drugs. Viruses. 2020;12(4):445. Available from: https://www.mdpi.com/1999-4915/12/4/445
- Zumla A, Chan JFW, Azhar EI, et al. Coronaviruses — drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15:327–347. Available from http://www.nature.com/articles/nrd.2015.37
- Li -C-C, Wang X-J. Three kinds of treatment with homoharringtonine, hydroxychloroquine or shRNA and their combination against coronavirus PEDV in vitro. Virol J. 2020;17(1):71. Available from: https://virologyj.biomedcentral.com/articles/10.1186/s12985-020-01342-w
- Xia S, Liu Q, Wang Q, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res. 2014;194:200–210. Available from https://linkinghub.elsevier.com/retrieve/pii/S0168170214004122
- Zheng B-J, Guan Y, Hez M-L, et al. Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus. Antivir Ther. 2005;10(3):393–403.
- Guan Y. Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China. Science. 2003;302(5643):276–278. Available from: https://www.sciencemag.org/lookup/doi/10.1126/science.1087139
- Bosch BJ, Van Der Zee R, De Haan CAM, et al. The coronavirus spike protein is a class i virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77(16):8801–8811. Available from: https://jvi.asm.org/content/77/16/8801
- Park J-E GT. Lipidation increases antiviral activities of coronavirus fusion-inhibiting peptides. Virology. 2017;511:9–18.
- Xia S, Zhu Y, Liu M, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020;17:765–767. Available from http://www.nature.com/articles/s41423-020-0374-2.710.1038/s41423-02003742
- Xia S, Yan L, Xu W, et al. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019;5:eaav4580. Available from https://advances.sciencemag.org/lookup/doi/10.1126/sciadv.aav4580
- Xia S, Liu M, Wang C, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020;30(4):343–355. Available from: http://www.nature.com/articles/s41422-020-0305-x.
- Zhu Y, Yu D, Yan H, et al. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity. J Virol. [ Pfeiffer JK, editor. . 2020;94(14): Available from] https://jvi.asm.org/content/94/14/e00635-20
- Zhang G, Pomplun S, Loftis AR, Loas A, Pentelute BL. The first-in-class peptide binder to the SARS-CoV-2 spike protein. bioRxiv. 2020 Jan 1.
- Watson A, Ferreira L, Hwang P, et al. Peptide antidotes to SARS-CoV-2 (COVID-19). bioRxiv. 2020.
- Trabocchi A, Guarna A. Peptidomimetics in organic and medicinal chemistry. In: The art of transforming peptides in drugs. Wiley Online Library; 2014.
- Mabonga L, Kappo AP. Peptidomimetics: a synthetic tool for inhibiting protein–protein interactions in cancer. Int J Pept Res Ther. 2020;26(1):225–241. Available from: http://link.springer.com/10.1007/s10989-019-09831-5
- Rubin SJS, Tal-Gan Y, Gilon C, et al. Conversion of protein active regions into peptidomimetic therapeutic leads using backbone cyclization and cycloscan – how to do it yourself! Curr Top Med Chem. 2018;18(7):556–565. Available from. .
- Mojsoska B, Jenssen H. Peptides and peptidomimetics for antimicrobial drug design. Pharmaceuticals. 2015;8(3):366–415. Available from: http://www.mdpi.com/1424-8247/8/3/366
- Cunningham AD, Qvit N, Mochly-Rosen D. Peptides and peptidomimetics as regulators of protein–protein interactions. Curr Opin Struct Biol. 2017;44:59–66.
- Sillerud L, Larson R. Design and structure of peptide and peptidomimetic antagonists of protein- protein interaction. Curr Protein Pept Sci. 2005;6(2):151–169. Available from: http://www.eurekaselect.com/openurl/content.php?genre=article&=1389-2037&volume=6&issue=2&spage=151
- Kim Y, Lovell S, Tiew K-C, et al. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J Virol. 2012;11(21):11754–11762. Available from: https://jvi.asm.org/content/86/21/11754
- Lee T-W, Cherney MM, Huitema C, et al. Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide. J Mol Biol. 2005;353(5):1137–1151. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0022283605010570
- Buzon MJ, Seiss K, Weiss R, et al. Inhibition of HIV-1 Integration in ex vivo-infected CD4 T cells from elite controllers. J Virol. 2011;85:9646–9650. Available from https://jvi.asm.org/content/85/18/9646
- Vuong W, Khan M, Fischer C, et al. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. bioRxiv. 2020.
- Balzarini J, Keyaerts E, Vijgen L, et al. Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics. Antiviral Res. 2006;72(1):20–33. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0166354206000726
- Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun. 2004;318(3):719–725. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0006291X04008150
- Yamamoto N, Matsuyama S, Hoshino T, et al. Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. bioRxiv. 2020.
- Choy K-T, Wong AY-L, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020;178:104786. Available from https://linkinghub.elsevier.com/retrieve/pii/S016635422030200X
- Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe COVID-19. N Engl J Med. 2020;383(19):1827–1837. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2015301
- Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag. 2008;4:1023–1033.
- Drożdżal S, Rosik J, Lechowicz K, et al. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resist Updat. 2020;53:100719. Available from https://linkinghub.elsevier.com/retrieve/pii/S1368764620300480
- El Bairi K, Trapani D, Petrillo A, et al. Repurposing anticancer drugs for the management of COVID-19. Eur J Cancer. 2020;10:40–61. Available from https://linkinghub.elsevier.com/retrieve/pii/S0959804920305207
- Malik S, Gupta A, Zhong X, et al. Emerging therapeutic modalities against COVID-19. Pharmaceuticals. 2020;13(8):188. Available from: https://www.mdpi.com/1424-8247/13/8/188
- Sorbera L, Graul A, Dulsat C. Taking aim at a fast-moving target: targets to watch for SARS-CoV-2 and COVID-19. Drugs Future. 2020;45(4):239–244.
- Zhou Q, Wang D, Liu Y, et al. Solnatide demonstrates profound therapeutic activity in a rat model of pulmonary edema induced by acute hypobaric hypoxia and exercise. Chest. 2017;151(3):658–667.
- Risonjić A, Smajlović H, Šero A, et al. Evaluation of long-term efficacy of disease-modifying agents in patients with relapsing-remitting multiple sclerosis. Folia Med Fac Med Univ Saraev.2019;54:56–59.
- McGrath B. Unique aspects of pain reduction in osteoarthritis of the knee with LMWF-5A. Open access rheumatology: research and reviews. 2015;19-22. Available from: http://www.dovepress.com/unique-aspects-of-pain-reduction-in-osteoarthritis-of-the-knee-with-lm-peer-reviewed-article-OARRR
- Wu R, Wang L, Kuo H-CD, et al. An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Rep. 2020;6(3):56–70. Available from: http://link.springer.com/10.1007/s40495-020-00216-7
- Raval D, Rathod V, Maheshwari D, et al. Review of the available treatment for COVID-19. Int J Sci Res. 2020;9:308–318.
- Ram Kumar Pandian S, Arunachalam S, Deepak V, et al. Targeting complement cascade: an alternative strategy for COVID-19. 3 Biotech. 2020;10(11):479. Available from: http://link.springer.com/10.1007/s13205-020-02464-2
- Wolf T, Kann G, Becker S, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet. 2004;318(9976):1428–1435. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673614623849
- Campione E, Cosio T, Rosa L, et al. Lactoferrin as protective natural barrier of respiratory and intestinal mucosa against coronavirus infection and inflammation. Int J Mol Sci. 2020;21(14):4903. Available from: https://www.mdpi.com/1422-0067/21/14/4903
- Ahmadi K, Farasat A, Rostamian M, et al. Enfuvirtide, an HIV-1 fusion inhibitor peptide, can act as a potent SARS-CoV-2 fusion inhibitor: an in silico drug repurposing study. J Biomol Struct Dyn. 2021;1–11. Available from https://www.tandfonline.com/doi/full/10.1080/07391102.2021.1871958
- VanPatten S, He M, Altiti A, et al. Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics. Future Med Chem. 2020;12(18):1647–1656. Available from: https://www.future-science.com/doi/10.4155/fmc-2020-0180
- Vatansever E, Yang K, Kratch K, et al. Targeting the SARS-CoV-2 main protease to repurpose drugs for COVID-19. bioRxiv. 2020.